Allergocomponent diagnostics in the management of comorbid patients

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Molecular allergy diagnostics is indicated for patients with comorbid allergy pathology and established polyvalent sensitization. Polyvalent sensitization (simultaneous formation of specific antibodies to allergens from several sources, for example, to cat allergens, birch pollen allergens, strawberries) can manifest itself at any age and is observed in a significant number of patients with allergic diseases. In patients with polyvalent sensitization and / or cross-reactions to allergens of unrelated groups of allergens, the diagnostic search for the causative allergen is difficult. In such cases, molecular allergy diagnostics allows you to establish the spectrum of true sensitization, make a reasonable choice of pathogenetic therapy, predict the course of an allergic disease, prevent the development of severe systemic reactions, including anaphylaxis, carry out reasonable elimination measures in relation to food allergens, preserving the maximum set of nutrients in the patient’s diet. We have carried out work to identify polyvalent sensitization in patients using the ALEX2 allergy chip, recognized as an advanced method of multicomponent allergy diagnostics, which in one study detects specific antibodies to 300 allergens (120 allergens and 180 allergenic molecules) and determines the concentration of total immunoglobulin E (IgE) in the blood serum. The presented clinical examples demonstrate the high information content of the ALEX2 technology, clearly show the possibility of determining the spectrum of causative allergens, which subsequently determines the appointment of adequate treatment and prevents the development of complications, especially in comorbid patients. Allergy component diagnostics provides extensive and detailed information about the patient’s sensitization profile at the molecular level, makes it possible to predict urgent allergic reactions, as well as assess the effectiveness of ASIT and develop personalized recommendations for patients with allergic diseases and polyvalent sensitization to various allergens. The accumulated clinical data indicate the need for a comprehensive diagnostic and therapeutic approach to the management of comorbid patients with allergopathology, which significantly increases the effectiveness of treatment and the quality of life of this category of patients. Molecular allergy diagnostics is an important tool in the hands of an allergist, which plays a significant role not only in current scientific research, but also in everyday clinical work.

Full Text

Restricted Access

About the authors

Madina S. Shogenova

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Author for correspondence.
Email: shogmad@yandex.ru
ORCID iD: 0000-0001-8234-6977
SPIN-code: 3668-4485

MD, Dr. Sci. (Medicine), Assistant Professor

Russian Federation, Moscow

Svetlana H. Hutueva

Center for Allergology and Immunology

Email: allergo2010@mail.ru
ORCID iD: 0000-0002-4126-1202

MD, Dr. Sci. (Medicine), Professor

Russian Federation, 10a Marko Vovchok street, 360002, Nalchik, Kabardino-Balkarian Republic

Laura S. Shogenova

Center for Allergology and Immunology

Email: l_shogenova@list.ru
ORCID iD: 0000-0001-8048-1278

MD

Russian Federation, 10a Marko Vovchok street, 360002, Nalchik, Kabardino-Balkarian Republic

References

  1. Valenta R, Kraft D. Recombinant allergen molecules: Tools to study effector cell activation. Immunol Rev. 2001;179:119–127. doi: 10.1034/j.1600-065x.2001.790112.x
  2. Valenta R, Lidholm J, Niederberger V, et al. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy. 1999;29(7): 896–904. doi: 10.1046/j.1365-2222.1999.00653.x
  3. Steering Committee Authors; Review Panel Members. A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. World Allergy Organ J. 2020;13(2):100091. doi: 10.1016/j.waojou.2019.100091
  4. Van Gasse AL, Mangodt EA, Faber M, et al. Molecular allergy diagnosis: Status anno 2015. Clin Chim Acta. 2015;444:54–61. doi: 10.1016/j.cca.2015.02.012
  5. Buzzulini F, Da Re Mirella, Scala E, et al. Evaluation of a new multiplex assay for allergy diagnosis. Clin Chim Acta. 2019;493: 73–78. doi: 10.1016/j.cca.2019.02.025
  6. Melioli G, Bonifazi F, Bonini S, et al. The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms, Italian Board for ISAC (IBI). Clin Biochem. 2011;44(12):1005–1011. doi: 1016/j.clinbiochem.2011.05.007
  7. Harwanegg C, Laffer S, Hiller R, et al. Microarrayed recombinant allergens for diagnosis of allergy. Clin Exp Allergy. 2003;33(1):7–13. doi: 10.1046/j.1365-2222.2003.01550.x
  8. Harwanegg C, Hiller R. Protein microarrays for the diagnosis of allergic diseases: State-of-the-art and future development. Clin Chem Lab Med. 2005;43(12):1321–1326. doi: 10.1515/CCLM.2005.226
  9. Russian Association of Allergologists and Clinical Immunologists [electronic resource]. Federal clinical guidelines for the diagnosis of allergic diseases. Available from: https://raaci.ru/dat/pdf/klinicheskie_rekomendacii_po_diagnostike_az.pdf?ysclid=m0xtfl5z8q213883174. Accessed: 11.09.2024.
  10. Timoshenko DO, Pavlova KS, Kurbachyova OM, Il’ina NI. Molecular allergology place in allergen-specific immunotherapy. Russ J Allergy. 2022;19(3):336–345. EDN: FYLFOB doi: 10.36691/RJA1572
  11. Oganov OG, Denisov IN, Simanenkov VI, et al. Comorbidities in clinical practice. algorithms for diagnostics and treatment. Cardiovascular therapy and prevention. 2019;18(1):5–66. EDN: YXKKAP doi: 10.15829/1728-8800-2019-1-5-66
  12. Elisyutina OG, Fedenko ES, Smol’nikov EV, et al. The significance of component-resolved allergy diagnostics in atopic dermatitis patients when prescribing allergen-specific immunotherapy. Russ J Allergy. 2022;19(4):519–533. EDN: SHAKVR doi: 10.36691/RJA1588
  13. Fomina DS, Lebedkina MS, Nikitina EA, et al. Analysis of the sensitization spectrum in patients with severe allergic diseases using the Immunocap ISAC method. Russ J Allergy. 2024;21(1):55–73. EDN: AANNAJ doi: 10.36691/RJA15994

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright © Pharmarus Print Media, 2024



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies